

Gemini Stock Analysis Report

Based on the comprehensive analysis of the **AUROPHARMA.NS** technical and fundamental report (Reference Date: 2026-01-31), here is my assessment.

Step 1: Audit the Data

- **Data Present:**
 - **Price Action:** Daily and Weekly candlestick charts (3-year history).
 - **Trend Indicators:** EMA Clusters (20, 50, 200), Supertrend, and Bollinger Bands.
 - **Momentum:** RSI, MACD, and Relative Strength (RS) against the Benchmark (CNXPHARMA).
 - **Volume:** Volume moving averages and accumulation/distribution signals.
 - **Fundamentals:** Quarterly and Annual revenue/profit growth metrics.
 - **Data Missing:**
 - **Order Book/Depth:** No Level 2 data to gauge immediate supply/demand walls.
 - **Institutional Activity:** Specific FII/DII buying/selling flows for the current month.
 - **Confidence Level: High.** The report provides a complete technical picture including multi-timeframe analysis (Weekly/Daily/15min) and crucial volatility metrics (squeeze analysis).
-

Step 2: Analyze the Setup

Price Structure & Trend:* **The Good:** The stock is attempting a recovery. It is currently trading at **INR 1207.70**, which is above the critical **200-day EMA (1160.29)**. Holding the 200 EMA is a classic sign of long-term trend support. Furthermore, price has recently reclaimed the 20 and 50 EMAs, which are bunching together-often a precursor to an expansion move.* **The Bad:** The daily **Supertrend is still Negative (Sell)** with a resistance value at **1219.86**. The stock is trapped between the support of the EMAs (1160-1175) and the resistance of the Supertrend (1220) and Upper Bollinger Band (1245).

Momentum & Volume:* **MACD:** Shows a **Bullish Crossover** and is rising, indicating shifting momentum to the upside on the daily chart.* **RSI:** At **58.30**, it is in neutral-bullish territory with room to extend before becoming overbought.* **Volume:** This is a concern. The current volume (8.12M) is below the 20-day average (11.88M). The rally lacks strong conviction from institutional buyers (low volume on up moves).* **Relative Strength:** The stock has an RS Score of **54/100**. It is a "Weakening Leader." While short-term RS (1 Month) is improving, it is not yet outperforming the Pharma sector significantly.

Fundamental Context:* Short-term fundamentals are weak (Revenue -7.03% QoQ, Net Income -8.71% QoQ), which explains the lack of explosive volume. The trade relies strictly on technical structure repair.

Step 3: Formulate the Recommendation

Verdict: NO (Wait for Confirmation)

Rationale: While the setup is promising because it held the 200 EMA, entering exactly at INR 1207 is risky. You are buying directly into overhead resistance (Daily Supertrend at ~1220 and Upper Bollinger Band at ~1245). Given the low volume, a rejection at 1220 is a distinct possibility.

Gemini Stock Analysis Report

As a positional trader, we need price to clear the "noise" and confirm the trend reversal.

Conditional Plan:

- **Condition to Buy: Daily Close above INR 1225.**
 - *Why:* This clears the Daily Supertrend resistance (1219.86) and confirms a breakout from the EMA compression zone.
- **Entry Price: INR 1225 - INR 1230** (On the retest or breakout candle).
- **Stop Loss: INR 1155** (Closing Basis).
 - *Why:* This is just below the critical 200 EMA (1160). If it loses the 200 EMA again, the intermediate trend is broken.
- **Take Profit: INR 1350** (Target 1) and **INR 1400** (Target 2).
 - *Why:* INR 1350 aligns with previous consolidation highs (visible on the page 2 chart) offering a ~10% upside.
- **Time Horizon: 4-8 Weeks.**

Risk/Reward Ratio: ~1:1.8 to 1:2.5 (depending on entry). This fits the criteria for an intermediate positional trade.

News & Analyst Targets

As a stock research analyst, I have compiled the latest news, brokerage updates, and analyst targets for **Aurobindo Pharma (AUROPHARMA)** as of the final week of January 2026.

1) Latest News for AUROPHARMA (Week of Jan 26-31, 2026)

- **Govt. Impressed Minimum Import Price (MIP) - Major Positive:** On **January 29, 2026**, the Directorate General of Foreign Trade (DGFT) imposed a Minimum Import Price on specific antibiotics to curb cheap imports.
 - **Penicillin-G:** MIP fixed at **\$24/kg** (approx. INR 2,216).
 - **Amoxicillin:** MIP fixed at **\$30/kg** (approx. INR 2,733).
 - **6-APA:** MIP fixed at **\$37/kg** (approx. INR 3,405).
 - **Impact:** This is a significant positive for Aurobindo Pharma's subsidiary, **Lyfius Pharma**, which has recently commissioned a large 15,000 MT Penicillin-G plant under the government's PLI scheme. The MIP acts as a floor price, protecting domestic manufacturing margins from dumping.
- **Share Price Surge & Clarification:** The stock surged approximately **6-8%** following the MIP news. In response to a query on significant volume movement, the company clarified to stock exchanges on **Jan 30, 2026**, that the rally was market-driven based on the public DGFT notification and not due to any undisclosed company information.
- **Upcoming Q3 Earnings:** The Board of Directors is scheduled to meet on **February 9, 2026**, to approve the un-audited financial results for the quarter ended December 31, 2025.
- **New Subsidiary:** On **Jan 23, 2026**, the company incorporated a new wholly-owned step-down subsidiary, **Aurobindo Pharma Philippines, Inc.**, to expand its footprint in the Southeast Asian market.

2) Brokerage Upgrades & Downgrades

- **ICICI Securities (Upgrade Target):** In a report dated **Jan 30, 2026**, the brokerage maintained its **BUY** rating and **raised** its target price to **INR 1,500** (from INR 1,350). They cite the new MIP policy as a key catalyst that could lift the gross margins of the Pen-G project to ~60% in FY27.

Gemini Stock Analysis Report

- **Motilal Oswal (Reiteration):** The firm reiterated its **BUY** rating with a target of **INR 1,430** on **Jan 30, 2026**, noting that the MIP implementation will aid the ramp-up of the PLI Pen-G project and support domestic manufacturing.
- **Macquarie (Maintain Underperform):** Contrasting the bullish view, Macquarie maintained an **Underperform** rating with a target of **INR 1,010**, remaining cautious despite the policy support.
- **MarketsMojo (Downgrade):** Earlier in the cycle (Dec 2025), the platform downgraded the stock from Buy to **Hold**, citing a balanced risk-reward profile at current valuations.

3) Other Impacting News (Direct & Indirect)

- **US FDA Observations (Negative Hangover):** The company is still dealing with regulatory observations from late 2025.
 - **Unit-IV (APL Healthcare):** Received **5 observations** (Form 483) following an inspection in mid-December 2025.
 - **Unit-V (Apitoria Pharma - API):** Received **3 observations** in December 2025.
 - **Analyst Note:** While the MIP news is a strong positive, the resolution of these FDA observations is critical for the seamless launch of future products in the US market.
- **PLI Scheme Traction:** The government's move to restrict imports validates the success of the Production Linked Incentive (PLI) scheme, directly benefiting Aurobindo as one of the few players with end-to-end capabilities (Pen-G -> 6-APA -> Amoxicillin).

4) Latest Analyst & Brokerage Targets

Below is the summary of the latest price targets released or reiterated in **January 2026**.

| Brokerage / Firm | Rating | Target Price (INR) | Date / Status |
|---------------------|--------------|--------------------|-------------------------------------|
| ICICI Securities | BUY | 1,500 | Jan 30, 2026 (Raised from 1,350) |
| Motilal Oswal | BUY | 1,430 | Jan 30, 2026 (Reiterated) |
| Trendlyne Consensus | BUY | ~1,350 | Jan 31, 2026 (Avg. Estimate) |
| Macquarie | Underperform | 1,010 | Jan 30, 2026 (Maintained) |
| MarketsMojo | HOLD | N/A | Current Rating (Downgraded Dec '25) |

Analyst Summary: The consensus view has shifted to a more **bullish** stance this week due to the government's policy intervention (MIP), which directly improves the profitability visibility for Aurobindo's massive new capex projects. However, regulatory compliance (FDA) remains a key risk to monitor.


Stock Detailed Analysis Report

AUROPHARMA.NS

Current Price: ₹1207.70

Generated: 2026-01-31 11:36

AUROPHARMA.NS - 3 Year Daily Price Chart



Long-term Fundamental Analysis (4 Years)

| Metric | Is Growing? | Accelerating? | 1Y Growth | 3Y CAGR |
|------------|-------------|---------------|-----------|---------|
| Revenue | Yes | No | 9.31% | 10.33% |
| Net Income | Yes | Yes | 9.86% | 9.59% |
| ROE | No | Yes | 0.41% | -0.31% |
| EPS | Yes | Yes | 10.43% | 9.79% |

Short-term Fundamental Analysis (6 Quarters)

| Metric | Is Growing? | Recent QoQ | Avg QoQ |
|------------|-------------|------------|---------|
| Revenue | Yes | -7.03% | 1.23% |
| Net Income | No | -8.71% | -2.37% |
| ROE | Yes | 4.52% | 4.52% |
| EPS | No | 4.00% | -3.39% |

AUROPHARMA.NS - Relative Strength Analysis

== OVERVIEW ==:

| | |
|------------------|-------------------------|
| Benchmark Index: | ^CNXPHARMA |
| Sector: | Pharma |
| Classification: | Weakening Leader |
| RS Score: | 54.0/100 |
| : | |

== RS RATIOS ==:

| | |
|--------|------------------------|
| 1M RS: | 1.059 [Leader] |
| 3M RS: | 1.113 [Leader] |
| 6M RS: | 1.123 [Leader] |
| 1Y RS: | 0.981 [Neutral] |
| : | |

== TURNAROUND ANALYSIS ==:


| | |
|--------------------|---------------------|
| Turnaround Status: | Not Detected |
| : | |

SIGNAL CRITERIA::


| | |
|--------------------------|-------------------------|
| ✗ Emerging RS: | Not accelerating |
| ✓ Medium-term Lagging: | 1Y=0.981 (≤ 1.0) |
| ✓ Performance Improving: | 3M (+8.6%) > 6M (+7.6%) |

Relative Strength Analysis: AUOPHARMA.NS vs ^CNXPHARMA
Classification: Weakening Leader


Price Performance Comparison (Normalized)



RS Ratio Trends (Multiple Timeframes)




RS Composite Score Timeline



AUROPHARMA.NS - EMA Crossover Summary

| | |
|---------------------|-----------------------------|
| EMA 20: | 1169.12 |
| EMA 50: | 1174.97 |
| EMA 200: | 1160.29 |
| Trend Status: | Short-term Downtrend |
| Golden Cross Date: | 2025-11-26 00:00:00+05:30 |
| Golden Cross Price: | 1227.40 |


AUROPHARMA.NS EMA Crossover Analysis



AUROPHARMA.NS - Bollinger Bands Summary

| | |
|------------------------------|------------|
| Current Price: | 1207.70 |
| Upper Band: | 1245.56 |
| Middle Band (SMA 20): | 1175.87 |
| Lower Band: | 1106.18 |
| %B: | 0.7284 |
| Band Width: | 0.1185 |
| Status: | Upper Half |
| Signal: | None |


AUROPHARMA.NS Bollinger Bands (20, 2) Analysis



AUROPHARMA.NS - Supertrend Summary

| | |
|-----------------------|-------------------------|
| Status: | DOWNTREND (Sell) |
| Supertrend Value: | 1219.86 |
| Signal Identified On: | 2026-01-13 |

Supertrend Analysis for AUROPHARMA.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




AUROPHARMA.NS - MACD Summary

| | |
|--------------|--------------------------------|
| MACD Line: | -10.73 |
| Signal Line: | -11.91 |
| Histogram: | 1.18 |
| Trend: | Bullish |
| Momentum: | Weakening |
| Signal: | Bullish Crossover (Buy) |

AUROPHARMA.NS Price






AUROPHARMA.NS MACD (12, 26, 9)



AUROPHARMA.NS - Volatility Squeeze Summary

| | |
|-----------------------|--|
| BB Width: | 0.1185 |
| ATR: | 31.0571 |
| Total Signals: | 31 |
| Signal 1: | BB Squeeze at 2026-01-08 00:00:00+05:30 (Price: 1206.10) |
| Signal 2: | BB Squeeze at 2026-01-09 00:00:00+05:30 (Price: 1198.70) |
| Signal 3: | BB Squeeze at 2026-01-12 00:00:00+05:30 (Price: 1172.90) |
| Signal 4: | BB Squeeze at 2026-01-13 00:00:00+05:30 (Price: 1167.70) |
| Signal 5: | BB Squeeze at 2026-01-14 00:00:00+05:30 (Price: 1180.10) |

AUROPHARMA.NS - Volatility Squeeze Analysis



AUROPHARMA.NS - RSI-Volume Summary

| | |
|----------------------|---|
| Current RSI: | 58.30 |
| Current Volume: | 8127226 |
| Volume MA 20: | 1188099 |
| Bullish Divergences: | 1 |
| Bearish Divergences: | 2 |
| Bullish Div 1: | Date: 2025-02-03 00:00:00+05:30, Price: 1121.19 |
| Bearish Div 1: | Date: 2024-08-30 00:00:00+05:30, Price: 1563.53 |
| Bearish Div 2: | Date: 2025-10-13 00:00:00+05:30, Price: 1136.80 |

AUROPHARMA.NS RSI-Volume Divergence Analysis



AUROPHARMA.NS - Volume Analysis

== VOLUME ANALYSIS ==:

Status:

28 Signals Detected

:

2025-12-31 [-]:

Distribution Day

2026-01-07 [-]:

Climax Volume (Churning)

2026-01-09 [-]:

Distribution Day



2026-01-16 [-]:

Distribution Day

2026-01-21 [+]:

Selling Exhaustion (Bullish Div)

AUROPHARMA.NS - Volume Analysis



Multi-Timeframe Supertrend Analysis

| Timeframe | Status | Value | Last Price | Signal Date |
|-----------|------------------|---------|------------|-------------|
| 1 Week | UPTREND (Buy) | 1122.17 | 1207.7 | 2025-11-10 |
| 1 Day | DOWNTREND (Sell) | 1219.86 | 1207.7 | 2026-01-13 |
| 15 Min | UPTREND (Buy) | 1180.97 | 1198.9 | 2026-01-30 |

Multi-Timeframe MACD Analysis

| Timeframe | Trend | Momentum | Signal |
|-----------|---------|-----------|--------------------------|
| 1 Week | Bullish | Weakening | Bullish Crossover (Buy) |
| 1 Day | Bullish | Weakening | Bullish Crossover (Buy) |
| 15 Min | Bearish | Weakening | Bearish Crossover (Sell) |

AUROPHARMA.NS - 1 Week (Candlestick + EMAs)



AUROPHARMA.NS - 1 Day (Candlestick + EMAs)



AUROPHARMA.NS - 15 Min (Candlestick + EMAs)



Trendlyne Snapshot - AUROPHARMA_main

Markets
STARFOLIO
Alerts
F&O
MF
Reports
Screeners
Subscribe
Superstars
Portfolio
Watchlist
Insider Trades
Results
Data Downloader
More

IN

Login / Sign up

MARKETS / SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY / INDUSTRY : PHARMACEUTICALS / AUROBINDO PHARMA LTD.

Aurobindo Pharma Ltd. ¹

NSE: AUROPHARMA | BSE: 524804

Aurobindo Pharma Live Share Price Today, Share Analysis and Chart

Mid-range Performer
In 5 Starfolio Baskets

1207.70
57.10 (4.96%)

8.9M
NSE+BSE Volume
High volume today
NSE 30 Jan, 2026 3:31 PM (IST)

+
Watchlist

Portfolio

Alert

My Notes

TRADE STOCK

Overview
FORECASTER
STOCK REPORT
Buy Sell Zone
F&O
Financials
News
Reports
Technicals
Shareholding
Deals
Corporate Actions
Alerts
About

Aurobindo Pharma Key Metrics

Preset Metrics
My Metrics

| | | | | | | |
|---|----------|--|------|---|------|--|
| Market Capitalization > High in Industry | 70,143.4 | PE TTM > Below Industry Median | 20.5 | PEG TTM > Negative PEG TTM | -4.6 | Price to Book > Below Industry Median |
| Institutional holding current Qtr % > High in Industry | 41.6 | Revenue Growth Qtr YoY % > Below Industry Median | 6.3 | Operating Revenue growth TTM % > Below Industry Median | 7.3 | Net Profit Qtr Growth YoY % > Below Industry Median |
| Net Profit TTM Growth % > Negative Net Profit TTM Growth % | -4.4 | Operating Profit Margin Qtr % > Above Industry Median | 20.3 | Operating Profit Margin TTM % > Above Industry Median | 20.5 | Piotroski Score > Below Industry Median |
| Rel Perf vs Nifty50 quarter% > | 11.7 | Rel Perf vs Sector quarter% > | 13.9 | ROE Annual % > Above Industry Median | 10.7 | |

All financials are in INR Cr and price data in INR

Durability & Valuation Scores
Free SIGN IN to see details


Momentum Score ¹
55.1 / 100
Technically Neutral

FORECASTER
Please SUBSCRIBE to view forecasts

Mid-range Performer
These stocks have average quality, financial and technical momentum, indicating a mid range performer
View Similar
Embed DVM

Key Metrics
DVM
Price Chart
Forecaster
Financials
Technicals
Shareholding
Deals
Documents
Corporate actions
Company Profile

Trendlyne Snapshot - AUROPHARMA_forecaster



Aurobindo Pharma - AUROPHARMA - stock price prediction, stock forecast, target price, analyst ratings from 28 analysts

Aurobindo Pharma has a share price target of Rs 1308, revenue growth forecast of 4.8%, and profit growth estimate of 4.4% for FY26, based on top 28 analyst calls.



Upgrade Your Plan

You need to upgrade your subscription plan to access this feature

Upgrade Now

Sign in

SAMPLE DATA BELOW

